Neurocritical Care News

The FDA has issued a complete response letter to AstraZeneca for its supplemental biologics license application of Ultomiris to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

A global clinical-stage biopharmaceutical company announced positive biomarker data from its exploratory phase 1 electroencephalogram biomarker study of novel and selective Kv7.2/Kv7.3 activator BHV-700 to treat epilepsy.

Compared with absolute values, serum neurofilament light chain Z scores were linked to higher effect size metrics and more accurate estimation of persistent neuroaxonal damage in pediatric populations, per data from The Lancet Neurology.

The first patient has been dosed in a clinical trial with electron accelerator-produced Cu-67, according to a Wisconsin-based company specializing in radiopharmaceuticals for therapeutic and medical imaging applications announced.

A Philadelphia-area contract research organization has announced completion of a phase 1 clinical trial of CMX-2043, Ischemix Inc.’s novel, proprietary cytoprotective drug candidate to treat acute traumatic brain injury.

Young brain donors exposed to repetitive head impacts through contact sports displayed cognitive and neurobehavioral symptoms with or without a diagnosis of chronic traumatic encephalopathy, according to research from JAMA Neurology.

A Southern California-based bioscience firm has announced additional positive data on FDA-approved Ingrezza capsules to treat adults with chorea associated with Huntington’s disease.

Possible biomarkers of an adolescent’s risk for developing mental health issues include alterations in proteins involved with immune responses, blood coagulation and other pathways, data show.

A Bay Area-based biopharmaceutical company has announced initiation of a phase 1 clinical trial for its oral, small molecule SARM1 inhibitor, NB-4746, to treat a wide range of conditions affecting the central, peripheral and ocular nervous systems.

A clinical-stage biotechnology company announced that it has raised $150 million in funding to advance its neuromedicine platform.